218 related articles for article (PubMed ID: 30095976)
41. Dysregulation of the endothelin pathway in lymphangioleiomyomatosis with no direct effect on cell proliferation and migration.
Chebib N; Archer F; Bobet-Erny A; Leroux C; Cottin V
Sci Rep; 2018 Oct; 8(1):14698. PubMed ID: 30279475
[TBL] [Abstract][Full Text] [Related]
42. Autophagy: an 'Achilles' heel of tumorigenesis in TSC and LAM.
Yu J; Parkhitko A; Henske EP
Autophagy; 2011 Nov; 7(11):1400-1. PubMed ID: 21997371
[TBL] [Abstract][Full Text] [Related]
43. Doxycycline inhibits matrix metalloproteinase-2 secretion from TSC2-null mouse embryonic fibroblasts and lymphangioleiomyomatosis cells.
Moir LM; Ng HY; Poniris MH; Santa T; Burgess JK; Oliver BG; Krymskaya VP; Black JL
Br J Pharmacol; 2011 Sep; 164(1):83-92. PubMed ID: 21418186
[TBL] [Abstract][Full Text] [Related]
44. The Lymphangioleiomyomatosis Lung Cell and Its Human Cell Models.
Steagall WK; Pacheco-Rodriguez G; Darling TN; Torre O; Harari S; Moss J
Am J Respir Cell Mol Biol; 2018 Jun; 58(6):678-683. PubMed ID: 29406787
[TBL] [Abstract][Full Text] [Related]
45. Pathogenesis of multifocal micronodular pneumocyte hyperplasia and lymphangioleiomyomatosis in tuberous sclerosis and association with tuberous sclerosis genes TSC1 and TSC2.
Maruyama H; Ohbayashi C; Hino O; Tsutsumi M; Konishi Y
Pathol Int; 2001 Aug; 51(8):585-94. PubMed ID: 11564212
[TBL] [Abstract][Full Text] [Related]
46. Cross talk between LAM cells and fibroblasts may influence alveolar epithelial cell behavior in lymphangioleiomyomatosis.
Clements D; Miller S; Babaei-Jadidi R; Adam M; Potter SS; Johnson SR
Am J Physiol Lung Cell Mol Physiol; 2022 Feb; 322(2):L283-L293. PubMed ID: 34936509
[TBL] [Abstract][Full Text] [Related]
47. Multifocal micronodular pneumocyte hyperplasia and lymphangioleiomyomatosis in tuberous sclerosis with a TSC2 gene.
Maruyama H; Seyama K; Sobajima J; Kitamura K; Sobajima T; Fukuda T; Hamada K; Tsutsumi M; Hino O; Konishi Y
Mod Pathol; 2001 Jun; 14(6):609-14. PubMed ID: 11406664
[TBL] [Abstract][Full Text] [Related]
48. Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas.
Robb VA; Astrinidis A; Henske EP
Mod Pathol; 2006 Jun; 19(6):839-46. PubMed ID: 16575396
[TBL] [Abstract][Full Text] [Related]
49. The role of chemokines in migration of metastatic-like lymphangioleiomyomatosis cells.
Pacheco-Rodriguez G; Moss J
Crit Rev Immunol; 2010; 30(4):387-94. PubMed ID: 20666708
[TBL] [Abstract][Full Text] [Related]
50. MicroRNA-21 is induced by rapamycin in a model of tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM).
Trindade AJ; Medvetz DA; Neuman NA; Myachina F; Yu J; Priolo C; Henske EP
PLoS One; 2013; 8(3):e60014. PubMed ID: 23555865
[TBL] [Abstract][Full Text] [Related]
51. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.
Goncharova EA; Krymskaya VP
J Cell Biochem; 2008 Feb; 103(2):369-82. PubMed ID: 17541983
[TBL] [Abstract][Full Text] [Related]
52. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H
Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653
[TBL] [Abstract][Full Text] [Related]
53. TSC2 modulates cell adhesion and migration via integrin-α1β1.
Moir LM; Black JL; Krymskaya VP
Am J Physiol Lung Cell Mol Physiol; 2012 Oct; 303(8):L703-10. PubMed ID: 22923640
[TBL] [Abstract][Full Text] [Related]
54. Upregulation of acid ceramidase contributes to tumor progression in tuberous sclerosis complex.
Astrinidis A; Li C; Zhang EY; Zhao X; Zhao S; Guo M; Olatoke T; Mattam U; Huang R; Zhang AG; Pitstick L; Kopras EJ; Gupta N; Jandarov R; Smith EP; Fugate E; Lindquist D; Markiewski MM; Karbowniczek M; Wikenheiser-Brokamp KA; Setchell KDR; McCormack FX; Xu Y; Yu JJ
JCI Insight; 2023 May; 8(9):. PubMed ID: 36927688
[TBL] [Abstract][Full Text] [Related]
55. Signal transducer and activator of transcription 3 is required for abnormal proliferation and survival of TSC2-deficient cells: relevance to pulmonary lymphangioleiomyomatosis.
Goncharova EA; Goncharov DA; Damera G; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
Mol Pharmacol; 2009 Oct; 76(4):766-77. PubMed ID: 19596836
[TBL] [Abstract][Full Text] [Related]
56. Inhaled rapamycin solid lipid nano particles for the treatment of Lymphangioleiomyomatosis.
Landh E; Moir LM; Gomes Dos Reis L; Traini D; Young PM; Ong HX
Eur J Pharm Sci; 2020 Jan; 142():105098. PubMed ID: 31698038
[TBL] [Abstract][Full Text] [Related]
57. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
58. Chemokine-enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene.
Pacheco-Rodriguez G; Kumaki F; Steagall WK; Zhang Y; Ikeda Y; Lin JP; Billings EM; Moss J
J Immunol; 2009 Feb; 182(3):1270-7. PubMed ID: 19155472
[TBL] [Abstract][Full Text] [Related]
59. Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.
Yu J; Parkhitko AA; Henske EP
Proc Am Thorac Soc; 2010 Feb; 7(1):48-53. PubMed ID: 20160148
[TBL] [Abstract][Full Text] [Related]
60. Antibody αPEP13h reacts with lymphangioleiomyomatosis cells in lung nodules.
Valencia JC; Steagall WK; Zhang Y; Fetsch P; Abati A; Tsukada K; Billings E; Hearing VJ; Yu ZX; Pacheco-Rodriguez G; Moss J
Chest; 2015 Mar; 147(3):771-777. PubMed ID: 25411763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
